The Kidney Cancer Association is an exhibitor at this meeting and we hope to obtain more information concerning the clinical trial described in this article:

TLR9 is currently in a Phase 2 monotherapy trial in renal cell carcinoma

Idera Pharmaceuticals (AMEX: IDP) today announced two company presentations to take place during the Biotechnology Industry Organization 2006 Annual Meeting (BIO 2006) at the McCormick Center in Chicago, IL.

Idera Pharmaceuticals, Inc. (AMEX: IDP) is a Cambridge, Massachusetts biotechnology company focused on the discovery, development, and commercialization of targeted immune therapies based on modulation of Toll-like Receptors (TLRs). Drug candidates targeting TLRs have broad commercial potential in the areas of oncology, infectious disease and allergy/asthma. Idera's most advanced clinical candidate, IMO-2055 (or HYB2055), is an agonist of

TLR9 and is currently in a Phase 2 monotherapy trial in renal cell carcinoma, and in a Phase 1/2 chemotherapy combination therapy trial in solid tumors. Idera is collaborating with Novartis for the discovery, optimization, development and commercialization of TLR9 agonist drug candidates targeting TLR9 for asthma and allergy. Idera also has selected another TLR9 agonist, IMO-2125, as a lead candidate for infectious diseases. For more information, visit www.iderapharma.com.

 

What did you think of this article?

Liked
Disliked
No Opinion